A shareholder reduction plan is currently the most notable event for HAOHAI BIOTEC. On February 12, 2026, the company announced that shareholder Lou Guoliang, due to personal funding requirements, plans to reduce his holdings by no more than 1 million shares within three months starting three trading days after the announcement's disclosure. The reduction will be executed through block trades and centralized bidding, representing no more than 0.4337% of the company's total share capital. While this plan aligns with the shareholder's prior listing commitments, it may exert pressure on short-term market sentiment.

Regarding recent stock performance, the A-shares of HAOHAI BIOTEC (688366.SH) have shown relative weakness. As of the close on February 13, 2026, the share price was 45.91 yuan, down 1.21% for the day and accumulating a 2.28% decline over the past five trading sessions. Over the same period, the Hong Kong-listed shares (06826.HK) closed at 26.72 Hong Kong dollars, rising 2.06% on the day but experiencing a volatility range of 4.55% over five days. Capital flow data indicated a net outflow of approximately 1 million yuan from A-shares on February 13, reflecting near-term pressure on liquidity. From a technical perspective, the A-share price has fallen below the 5-day moving average of 46.22 yuan, with the MACD indicator showing a bearish crossover signal. The Hong Kong shares are trading near the Bollinger Band midline of 26.034 Hong Kong dollars, while the J-line of the KDJ indicator has risen to 78.96, suggesting short-term overbought conditions.

The company's financial results for the third quarter of 2025 showed a decline. Quarterly revenue decreased by 11.29% year-over-year to 595 million yuan, while net profit attributable to shareholders fell 11.39% to 93.58 million yuan. For the first three quarters cumulative revenue declined 8.47% year-over-year, with net profit down 10.63%. The gross margin remained stable at 70.39%, but non-GAAP net profit saw a significant decrease of 44.54%, primarily attributed to increased sales expenses and market conditions.

Institutional perspectives on HAOHAI BIOTEC's long-term fundamentals remain attentive. Recent data shows that two institutions issued views on the Hong Kong-listed shares in February 2026, all maintaining Buy or Outperform ratings. Their average target price is 56.65 Hong Kong dollars, indicating potential upside from the current price. Analysts generally focus on the company's progress in expanding its medical device business internationally and advancing its high-end product lines, though the near-term shareholder reduction event may temporarily constrain valuation recovery.